LFST Filings — Lifestance Health Group, Inc. - FilingSpy
LFST
Lifestance Health Group, Inc.
A provider of outpatient mental health care, LifeStance offers therapy, psychiatric evaluations, and psychological testing in person and online across dozens of states, treating over a million patients a year. Founded in 2017, it grew by buying up local practices and rebranding them under one national name chosen to signal a "life-centered" approach to care rather than any single clinic brand.
LifeStance posts $30.7M in operating income as Center Margin rises 41% on 26% revenue growth.
LifeStance delivered its highest quarterly on record. rose 26% to $435.4 million and operating income reached $30.7 million, as a 41% increase in to $153.0 million drove a swing from a net loss a year ago to of $23.6 million. The company is now generating cash and buying back stock, but concentrated shareholder control and unremediated internal control weaknesses remain open questions.
Key takeaways
reached $30.7 million, up from a $3.0 million loss a year ago, as expanded to $153.0 million from $108.4 million.
rose 26% to $435.4 million, driven by a 19% increase in patient visits from 834 net new clinicians and higher clinician productivity.
Center costs grew 19%, trailing the 26% increase, which produced the 41% rise in — the widest gap between revenue and cost growth in two years.
Section summaries
Management's Discussion and Analysis
Revenue grew 26% YoY to $435.4M in Q2 2026, driven by clinician growth and productivity, swinging to net income of $23.6M.
⌄
Total increased 26% to $435.4M in Q2 2026, primarily from a 19% rise in patient visits driven by a net increase of 834 clinicians and higher productivity.
rose 41% to $153.0M in Q2 2026, as growth of 26% outpaced a 19% increase in center costs, which were driven by higher clinician compensation.
swung to $23.6 million from a $3.8 million loss in Q2 2025, aided by the and lower .
reached $99.9 million for the quarter, and was $87.9 million, both more than double the prior-year period.
The company repurchased $97.6 million in stock during the first half of 2026 under a new $100 million authorization, reducing the cash balance to $225.9 million from $248.6 million at year-end 2025.
What changed
Earlier filings flagged whether net profitability could be sustained: Q2 2026 of $23.6 million is the fourth consecutive quarter of positive net income and the largest yet, settling the question of whether the first full-year profit in FY 2025 was a one-off.
The trajectory of was flagged after cost growth matched growth in FY 2025: in Q2 2026, center costs grew 19% while revenue rose 26%, a clear re-acceleration of after two quarters where the gap had narrowed.
The privacy-related class action over website pixel technologies remains unresolved and is referenced again in this filing's legal proceedings section, with no charge recorded.
The material weaknesses in internal control over financial reporting remain unremediated, and the company is now in a one-year transition away from Nasdaq controlled-company status, leaving board committees not yet fully independent.
What to watch
Whether expansion can be sustained at the Q2 pace, or if cost growth will again converge with growth as clinician compensation rises with visit volume.
The pace and scale of remaining stock repurchases under the new authorization and their effect on the $225.9 million cash balance.
Any development in the privacy-related class action over website pixel technologies, which remains an unresolved risk that could create a material charge.
Whether the material weaknesses in internal control are remediated before the auditor attestation, now that the company is transitioning away from controlled-company exemptions.
General and administrative expenses grew 11% to $108.1M in Q2 2026, mainly due to higher salaries, marketing, and professional fees, partially offset by lower .
The company swung to of $23.6M in Q2 2026 from a net loss of $3.8M a year ago, aided by and lower .
was $133.0M for the first half of 2026, while $97.6M was used to 13 million shares under a new $100M repurchase program.
Management expects continued growth from clinician recruiting, acquisitions, and new centers, alongside increasing center and G&A costs to support expansion.
Quantitative and Qualitative Disclosures About Market Risk
Market risk represents the risk of loss that may impact our financial condition due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financi…
⌄
Market risk represents the risk of loss that may impact our financial condition due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.
Interest Rate Risk
Our primary market risk exposure is changing prime rate-based interest rates. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control. We may from time to time utilize interest rate swaps to manage overall borrowing costs under our credit facilities and reduce exposure to adverse fluctuations in interest rates.
As of June 30, 2026, we had an aggregate principal amount of $275.5 million outstanding under our credit facilities. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on our business, financial condition or results of operations.
Inflation Risk
Based on our analysis of the periods presented, we believe that inflation has not had a material effect on our operating results. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.
24
For a discussion of certain legal proceedings in which we are involved from time to time, please read Note 12, Commitments and Contingencies, to our unaudited consolidated financial statements in this report, which is incorporated into this item by reference.
⌄
For a discussion of certain legal proceedings in which we are involved from time to time, please read Note 12, Commitments and Contingencies, to our unaudited consolidated financial statements in this report, which is incorporated into this item by reference.
Principal stockholders hold 35.4% of common stock, enabling significant influence over governance and change-of-control decisions.
⌄
TPG and Summit affiliates collectively own 35.4% of common stock, allowing them to significantly influence board composition, management, and key stockholder approvals.
This concentrated ownership could block unsolicited acquisitions, potentially depriving public stockholders of a control premium and affecting the market price.
Principal stockholders and their affiliates may invest in competing or complementary businesses, creating conflicts of interest without a duty to refrain from such activities.
The company ceased to be a Nasdaq 'controlled company' and is in a one-year transition to fully independent board committees, leaving stockholders without full governance protections during that period.